Wedbush Raises Harpoon Therapeutics (NASDAQ:HARP) Price Target to $7.00

Harpoon Therapeutics (NASDAQ:HARPGet Rating) had its price target raised by Wedbush from $5.00 to $7.00 in a research report sent to investors on Monday morning, MarketBeat reports. Wedbush currently has an outperform rating on the stock.

HARP has been the topic of a number of other research reports. Robert W. Baird reduced their target price on Harpoon Therapeutics from $35.00 to $14.00 in a report on Monday, March 14th. Roth Capital decreased their target price on Harpoon Therapeutics from $31.00 to $14.00 in a research report on Monday, March 14th. Zacks Investment Research downgraded Harpoon Therapeutics from a buy rating to a hold rating in a research note on Friday, March 11th. Piper Sandler reduced their price target on shares of Harpoon Therapeutics from $15.00 to $14.00 in a research note on Friday, May 13th. Finally, SVB Leerink lowered their price objective on shares of Harpoon Therapeutics from $19.00 to $13.00 in a research report on Friday, March 11th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Buy and a consensus target price of $15.19.

Harpoon Therapeutics stock opened at $2.52 on Monday. The firm has a market cap of $83.37 million, a PE ratio of -1.09 and a beta of 1.54. The stock’s fifty day moving average price is $3.46 and its two-hundred day moving average price is $5.18. Harpoon Therapeutics has a one year low of $1.73 and a one year high of $22.74.

Harpoon Therapeutics (NASDAQ:HARPGet Rating) last announced its quarterly earnings data on Thursday, March 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.20). Harpoon Therapeutics had a negative return on equity of 99.99% and a negative net margin of 366.46%. The firm had revenue of $4.33 million for the quarter, compared to analyst estimates of $7.03 million. On average, equities analysts expect that Harpoon Therapeutics will post -2.18 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Delphia USA Inc. acquired a new stake in Harpoon Therapeutics during the 1st quarter worth about $57,000. Goldman Sachs Group Inc. grew its stake in Harpoon Therapeutics by 44.1% during the first quarter. Goldman Sachs Group Inc. now owns 161,567 shares of the company’s stock worth $803,000 after purchasing an additional 49,467 shares during the period. State Street Corp increased its holdings in Harpoon Therapeutics by 15.3% in the first quarter. State Street Corp now owns 443,269 shares of the company’s stock worth $2,203,000 after purchasing an additional 58,911 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Harpoon Therapeutics by 309.3% in the first quarter. Renaissance Technologies LLC now owns 211,200 shares of the company’s stock valued at $1,050,000 after buying an additional 159,600 shares during the period. Finally, Tekla Capital Management LLC bought a new position in shares of Harpoon Therapeutics during the 1st quarter worth approximately $1,292,000. Institutional investors and hedge funds own 81.07% of the company’s stock.

Harpoon Therapeutics Company Profile (Get Rating)

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors.

See Also

Analyst Recommendations for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.